Zusammenfassung
Mittels prospektiv-randomisierter klinischer Studien der Deutschen Hodgkin Studiengruppe (DHSG) konnten in den letzten 40 Jahren systematisch Verbesserungen im Bereich von Strahlen- und Polychemotherapie umgesetzt werden. So entwickelte sich das Hodgkin-Lymphom von einer unheilbaren malignen Erkrankung zu derjenigen Malignität mit der besten Prognose in der Erwachsenenonkologie. Neben den Verbesserungen der Therapieergebnisse konnten auch diagnostische Standards weiter entwickelt werden. Wesentliches Strukturmerkmal der DHSG ist die multidisziplinäre Zusammenarbeit von internistischer Onkologie, Strahlentherapie, diagnostischer Radiologie, Nuklearmedizin und Biostatistik. In 5 aufeinander folgenden Studiengenerationen zur Primärtherapie des Hodgkin-Lymphoms konnte durch intensive Kooperation verschiedener Fachbereiche auch ein Beitrag zur Qualitätssicherung geleistet werden.
Abstract
Over the past 40 years, treatment of Hodgkin’s lymphoma has changed from an almost fatal prognosis to a prototype illness for curative treatment strategies in adult oncology. A substantial impact on this development was contributed by the prospective-randomized clinical trials organised by the German Hodgkin Study Group. In addition to improvements in therapy outcome, the trial work provided benefits in diagnostics and quality assurance. Close collaboration between medical oncology, radiotherapy, radiology, nuclear medicine, and biostatistics is characteristic of the GHSG.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Schwab U, Stein H, Gerdes J et al. (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin‘s disease and a subset of normal lymphoid cells. Nature 299:65–67
Diehl V, Pfreundschuh M, Loeffler M et al. (1989) Chemothrapy of Hodgkin‘s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbarzine, prednisone) and ABVD (doxorubicine, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 6:155–162
Duhmke E, Franklin J, Pfreundschuh M et al. (2001) Low-dose radiation is sufficient fort he noninvolved extended-field treatment in favorable early-stage Hodgkin‘s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914
Sieber M, Tesch H, Pfistner B et al. (2002) Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin‘s lymphoma: final results of the German Hodgkin‘s Lymphoma Study Group Trial HD5. J Clin Oncol 20:476–484
Sieber M, Tesch H, Pfistner B et al. (2004) Treatment of advanced Hodgkin‘s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin‘s Lymphoma Study Group Trial HD6. Ann Oncol 15:276–282
Sieber M, Franklin J, Tesch H et al. (2002) Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin‘s disease: results of the German Hodgkin‘s Lymphoma Study Group Trial HD7. Blood 100:A341
Engert A, Schiller P, Josting A et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin‘s lymphoma: results of the HD8 trial of the German Hodgkin‘s Lymphoma Study Group. J Clin Oncol 19:3601–3608
Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOP chemotherapy compared with COPP/ABVD for advanced Hodgkin‘s disease. N Engl J Med 348:2386–2395
Diehl V, Stein H, Hummel M et al. (2003) Optimisation of combined modality treatment intensity in early stage Hodgkin‘s lymphoma: interim results of the HD10 trial of the GHSG. ASH Educational Book
Diehl V, Stein H, Hummel M et al. (2003) Intensification of chemotherapy and concomitant dosis reduction of radiotherapy in intermediate stage Hodgkin‘s lymphoma: interim results of the HD11 trial of the GHSG. ASH Educational Book
Diehl V, Engert A, Schiller P et al. (2003) Comparison of 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without radiotherapy for advanced stage Hodgkin‘s lymphoma: preliminary results of the HD12 trial of the GHSG. ASH Abstract
Sieber M, Bredenfeld H, Josting A et al. (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:1734–1739
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514
Diehl V, Sieber M et al. (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin‘s disease. The German Hodgkin‘s Lymphoma Study Group. Ann Oncol 8:143–148
Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63:1727–1733
Pfaff H et al. Versorgungsforschung — Begriffsbestimmung, Gegenstand und Aufgaben in Gesundheitsversorgung und Disease Management — Grundlagen und Anwendungen der Versorgungsforschung. Huber, Bern, pp 13–23
Interessenkonflikt:
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bredenfeld, H., Engert, A. & Diehl, V. 25 Jahre Deutsche Hodgkin Studiengruppe. Onkologe 12, 337–344 (2006). https://doi.org/10.1007/s00761-005-1017-z
Issue Date:
DOI: https://doi.org/10.1007/s00761-005-1017-z